Compare · CCEL vs MGRX
CCEL vs MGRX
Side-by-side comparison of Cryo-Cell International Inc. (CCEL) and Mangoceuticals Inc. (MGRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCEL and MGRX operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- CCEL carries a market cap of $83.3M.
- Over the past year, CCEL is down 36.5% and MGRX is down 75.8% - CCEL leads by 39.4 points.
- CCEL has hit the wire 2 times in the past 4 weeks while MGRX has been quiet.
- Company
- Cryo-Cell International Inc.
- Mangoceuticals Inc.
- Price
- $3.59-2.18%
- $0.43+8.01%
- Market cap
- $83.3M
- -
- 1M return
- +16.56%
- +34.71%
- 1Y return
- -36.46%
- -75.84%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 2023
- News (4w)
- 2
- 0
- Recent ratings
- 0
- 0
Cryo-Cell International Inc.
Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Latest CCEL
- SEC Form 10-Q filed by Cryo-Cell International Inc.
- Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2026 Financial Results
- Cryo-Cell International Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Cryo-Cell Receives NYSE American Continued Listing Notice
- SEC Form 10-K filed by Cryo-Cell International Inc.
- Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2025
- SEC Form 4 filed by Chairman, Co-CEO Portnoy David
- SEC Form 4 filed by Co-CEO Portnoy Mark L.
- SEC Form 4 filed by Chief Information Officer Mikulinsky Oleg
- SEC Form 4 filed by VP Finance, CFO Taymans Jill M
Latest MGRX
- SEC Form 10-K filed by Mangoceuticals Inc.
- SEC Form NT 10-K filed by Mangoceuticals Inc.
- SEC Form 4 filed by Cohen Jacob D.
- SEC Form 4 filed by Cohen Jacob D.
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study
- Mangoceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits